Backed by market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, wider supply chain intelligence, emerging startup coverage, and detailed product-level insights, The Business Research Company’s 2026 market reports are designed to offer research that is more actionable and strategically valuable than ever.
Ticovac Market Growth Potential: How Will Market Size Shift Through 2030?
The ticovac market size has demonstrated significant expansion in recent years. It is projected to expand from $4.31 million in 2025 to $4.63 million in 2026, achieving a compound annual growth rate (CAGR) of 7.5%. The historical expansion can be attributed to factors such as the endemic presence of tick-borne encephalitis, various public health vaccination initiatives, increased exposure due to outdoor activities, hospital-based immunization programs, and regulatory approvals for TBE vaccines.
The ticovac market is projected to experience robust expansion over the coming years, set to reach $6.11 million in 2030, exhibiting a compound annual growth rate (CAGR) of 7.2%. Key factors driving this growth during the forecast period include the widening of vaccination coverage across Europe, increased travel to areas where the disease is prevalent, a surge in tick populations influenced by climate change, the implementation of more robust preventive healthcare strategies, and greater investment in vaccine infrastructure. Significant trends anticipated in the same period involve a heightened demand for tick-borne disease vaccinations, the broadening scope of preventive travel immunization, an increase in government-sponsored vaccination initiatives, elevated public awareness regarding vector-borne diseases, and enhancements in cold chain vaccine distribution.
Get A Free Sample Report With In-Depth Market Insights:
Ticovac Market Growth Momentum: What Factors Are Shaping Demand?
The increasing occurrence of tick-borne diseases is projected to propel the expansion of the ticovac market in the future. These ailments are human illnesses transmitted by bites from infected ticks, resulting from bacteria, viruses, or parasites. The increase in tick-borne diseases stems from factors such as climate change, the enlargement of tick living areas, greater human contact, and enhanced diagnostic methods. Ticovac is crucial for addressing tick-borne diseases because it delivers active immunity against tick-borne encephalitis (TBE), a severe viral infection potentially spread via tick bites. As an illustration, in February 2024, data from the Centers for Disease Control and Prevention, a US-based government agency, indicated that the total incidence of Lyme disease stood at 18.9 cases per 100,000 population, marking a rate 68.8% higher than in prior years. In areas with high incidence, the median rate was 58% higher, reaching 68.3 cases per 100,000, while for children aged 5–9 years, the incidence reached 16.5 cases per 100,000, showing an 11.5% increase. Consequently, the rising prevalence of tick-borne diseases is fueling the growth of the ticovac market.
Ticovac Market Segment Performance And Emerging Opportunities
The ticovac market covered in this report is segmented –
1) By Formulation: Inactivated Vaccines, Live Attenuated Vaccines
2) By Indication: Tick-Borne Encephalitis, Japanese Encephalitis, Rabies Encephalitis
3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
Ticovac Market Trends Redefining Industry Growth
Leading firms within the ticovac sector are concentrating on advanced formulations, like suspension liquid, to achieve a competitive advantage in the market. This suspension liquid represents a vaccine formulation developed to prevent tick-borne encephalitis, administered via intramuscular injection. Each dose is 0.5 mL and is suitable for both adult and pediatric patients. As an illustration, in September 2024, Pfizer Inc., a US-based pharmaceutical company, introduced Ticovac, a vaccine intended to prevent tick-borne encephalitis (TBE), which is a viral infection impacting the brain and spinal cord. This vaccine marks the initial introduction of its type in Japan, providing defense against the illness in areas where it is common. There are two variants of the vaccine available, one specifically for adults and another for children, both administered as a 0.5 mL intramuscular injection.
Ticovac Market Key Players: Which Companies Lead Industry Competition?
Major companies operating in the ticovac market are Pfizer Inc.
View The Full Ticovac Market Report:
Ticovac Market Largest Region: Which Geography Holds The Highest Market Share?
Europe was the largest region in the ticovac market in 2025. North America is expected to be the fastest-growing region in the forecast period. The regions covered in the ticovac market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
